GLP-1s in 2027: The Decision Every Employer Is Being Forced to Make
Employer coverage of weight-loss GLP-1s fell from 72% to 60% in a year, and more are dropping it for 2027. Doug Foreman on the real cost per employee, the options between cover-everything and cover-nothing, and how to talk to your people about it.
A client called me in September, a manufacturer with about 180 employees, and said, "Doug, I just got a report that says eleven people on our plan are on Wegovy and it is costing me more than our dental plan. What do I do?" I have had some version of that call every week since.
I do not think there is a right answer that works for every employer. But I think there is a wrong one, which is not deciding and letting the renewal decide for you.
What this actually costs
For weight-loss indications, employers are paying somewhere in the mid-$500s to mid-$600s per user per month after rebates. Eleven users at that rate is roughly $75,000 to $85,000 a year. For a group of 180, that is real money, and it is growing: about 11% of American adults are now on a GLP-1 for weight loss, and the carriers are attributing roughly a full point of 2027 trend to this one drug class.
What other employers are doing
The share of employers covering GLP-1s for weight loss dropped from 72% in 2025 to 60% in 2026. For 2027, another 14% say they have dropped or plan to drop it. So the trend is clear, but I want to be careful here, because "drop it" is not the only move and in some groups it is not the best one.
The options in between
Most of our clients are landing somewhere in the middle.
Tighten the clinical criteria. Roughly 69% of employers now confirm eligibility with biometrics, and 45% require participation in a structured program. That keeps the drug available for the people it is intended for and screens out the prescriptions that were written after a five-minute telehealth visit.
Pair it with a program. Vendors like Omada and others bundle coaching and nutrition with the medication, and some will tie their fee to outcomes. The clinical data on keeping weight off after stopping the drug is not great, so a program that builds habits is not a soft add-on. It is how you avoid paying for the same drug forever.
Step outside the plan. About 8% of employers are pointing employees to the manufacturers' direct-to-consumer programs, where the cash price is lower than what the plan pays, and another 30% are considering it. Some are reimbursing a fixed amount through an HRA instead of running it through the pharmacy benefit. This is newer and it is not for everyone, but for a smaller group it can be the difference between covering something and covering nothing.
Cover diabetes only. This is where a lot of groups end up. It is defensible, it is simple to administer, and it is honest about what the plan can afford.
How to tell your employees
Whatever you decide, say it plainly and say it before enrollment, not after a claim gets denied. If you are tightening criteria, explain what the criteria are. If you are dropping weight-loss coverage, tell people what the alternatives are and give them the direct-purchase information. An employer that explains a hard decision keeps more trust than one that hides a good one.
My advice
Get the utilization report from your carrier or PBM this month. Know your number. Then pick one of the paths above on purpose. We will model each option against your actual claims so you are choosing with real figures, not a headline.
This article is for general informational and educational purposes only and does not constitute insurance, legal, tax, or financial advice. For guidance specific to your organization, talk with an FBP advisor.
Want this applied to your plan?
Our advisors turn insights like these into a concrete strategy for your workforce. Start with a free benchmark analysis.